Virta Health payer-contract structure — 100% fees-at-risk, additive (not substitutive) to LLY thesis

Verdict (one line)

Virta runs a 100%-performance-based, outcomes-tied contract model with self-insured employers, health plans, and ASO administrators — closer to a pay-for-clinical-outcome shared-savings shape than to capitation or PMPM. Pricing is structured per-engaged-member ($2,808 year-one / $2,388 thereafter for the diabetes program, $900-$950/year for newer sustainable-weight-loss / nutrition-only tracks), with 2025-2026 cost guarantees including 0% YoY GLP-1 utilization growth and 1:1 claims-based ROI. The contract shape supports rather than threatens the LLY-longevity-v1 thesis — Virta is structurally complementary (lifestyle + ketogenic protocol + de-prescription), not substitutive, to GLP-1 prescribing. Where it matters: Virta's new "0% YoY GLP-1 growth guarantee" is the most concrete anti-GLP-1-as-only-tool market signal to date, and is the strongest argument for keeping the LLY bear case calibrated against the "lifestyle-first reversal at scale" alternative.

The question

What's the structure of Virta Health's payer contracts (capitation vs shared-savings vs PMPM vs outcomes-based), how does pricing reconcile with the 13% sustained body-weight loss claim, and does that contract shape constrain or accelerate the LLY-longevity-v1 thesis (additive value capture vs substitutive)?

What we already know (from the vault)

[[2026-05-22-tim-ferriss-sami-inkinen-virta-t2d-rowing]] — Sami Inkinen episode tags directly as input to LLY-longevity-v1. Virta's pitch is reversal via ketogenic / very-low-carb protocol, not symptom-management. Claims sustained 13% body-weight loss + meaningful T2D-reversal rates (HbA1c <6.5% without medication). Not a pharma play; complementary to GLP-1 prescribing in the same patient population.
[[2026-05-21-lilly-glp1-longevity-thesis]] — LLY-longevity-v1 is anchored on GLP-1 franchise dominance (Mounjaro/Zepbound, retatrutide TRIUMPH-1, orforglipron oral). Bear case explicitly includes "Medicare negotiation includes Mounjaro/Zepbound at unfavorable price." Virta's contract structure is a relevant input because it's the most credible "lifestyle-first costs less than GLP-1" demonstration to payers — if Virta scales, payers gain BATNA on GLP-1 pricing negotiations.
[[2026-05-11-marchione-primary-care]] — Primary-care unit economics don't work in fee-for-service (median operating margin 1.7%; primary care subsidized by specialist/procedure revenue). Virta's outcomes-based ASO/self-insured-employer model is one of the few VBC shapes that escapes this trap by going around primary care entirely (digital-first virtual clinic, no hospital affiliation).
[[2026-05-10-data-sovereignty-outcome-procurement-bet-architecture]] — Virta is the most successful operating example of "outcomes-based contracting at scale" in the cardiometabolic vertical. Their 550 B2B customers + $158M annualized revenue make it the load-bearing comp for the RDCO patient-data-sovereignty bet's VBC leg.

What the web says

100% fees-at-risk model (since June 2024): Virta moved the entire commercial book to performance-based contracts tied to T2D reversal outcomes for employer and health-plan partners. Estimated employer/payer savings of $9,600 per patient over first 24 months (Fierce Healthcare 100% fees at risk; Virta blog "Putting Our Money Where Our Medicine Is").
Pricing structure: Diabetes reversal program $2,808 year-one / $2,388 subsequent years per patient. Newer programs: Sustainable Weight Loss $900/year, Diabetes Management $950/year (Sacra). PMPM gross savings of $503 per engaged member per month claimed.
Customer base scale (2025): ~550 B2B customers covering 12M+ US lives, average revenue per customer ~$290K (Sacra Virta Health profile).
2025 cost guarantees (industry-first):
- 0% YoY growth guarantee in GLP-1 utilization with guaranteed weight-loss outcomes
- 1:1 claims-based ROI guarantee for nutrition-only programs (at least dollar-for-dollar savings vs fees paid)
- $425 PMPM cost-reduction claim for engaged patients ($10,000 over first 2 years)
Customer concentration (2025-2026): ASO partnerships growing — Providence Health Plan rolled out to "growing roster of ASO groups" (Providence Health Plan press). Carrum Health partnership announced 2026 to deliver "full-spectrum weight management" to self-insured employers (Carrum Health press). Capital Rx launched "Rx Reverse" co-product specifically positioning Virta as the de-prescription alternative to GLP-1s for T2D + obesity populations (Judi Health Capital Rx Rx Reverse).
Revenue trajectory: $107.5M annualized end-2024 → $158M annualized August 2025 (+80% YoY). 550 customers / $290K avg ARPU.
CMS exposure (2026): Virta selected as early adopter in CMS Health Tech Ecosystem Initiative, Diabetes & Obesity Prevention and Management pillar; milestones expected by early 2026, opening Medicare + Medicaid access.

Convergences and contradictions

Convergence: Vault (Inkinen episode 2026-05-22) and web (Virta 2024 fees-at-risk announcement) both confirm the contract structure is 100% outcomes-based, NOT capitation or pure PMPM. The risk-bearing falls entirely on Virta — payers only pay when measured clinical outcomes (HbA1c reduction, weight loss, medication de-prescription) are achieved. This is a stronger structural commitment than the typical VBC shared-savings model.
Convergence: $2,808 year-one pricing × 13% weight-loss outcome maps cleanly to the employer-savings claim ($9,600 / 24mo ≈ $400/month avoidance). The math is consistent across Sacra, Virta blog, and Fierce Healthcare.
Contradiction with one mental model: A reader might assume "outcomes-based" means small upside cap per patient — but Virta's pricing is flat per-engaged-member (not a percentage of savings), so when the program works at scale (~70% T2D reversal in their published case-mix), the unit economics are strong. The "100% fees at risk" framing is a marketing wrapper around what is effectively a risk-shifted bundled-care fee with eligibility hurdles, not a true pure-shared-savings split.
Convergence with LLY-longevity-v1 bear case: Virta's 0% YoY GLP-1 utilization growth guarantee is exactly the kind of structured market BATNA that gives payers pricing leverage against Lilly/Novo at formulary negotiation. The LLY thesis already lists "US Medicare negotiation includes Mounjaro/Zepbound at unfavorable price" as a primary disqualifier — Virta's contract shape gives that disqualifier a named operating mechanism.
Contradiction with simple substitution framing: Virta is NOT a pure substitute for GLP-1 prescribing. The Carrum Health partnership (2026) explicitly positions Virta as "full-spectrum weight management" — and Sami Inkinen has publicly framed GLP-1 as appropriate for the subset of patients lifestyle protocols don't reach. The dominant 2026 framing in published partnership language is complementary triage (Virta first for lifestyle-responsive cases; GLP-1 for the rest), not substitution.

Synthesis for RDCO

Contract-shape answer: Virta runs a 100%-performance-based bundled-fee model with self-insured employers and ASO/health-plan partners. Pricing is flat per-engaged-member ($2,808/$2,388 for diabetes; $900-$950 for newer lighter tracks), with payment tied to clinically-significant outcomes (HbA1c reduction, weight loss, medication de-prescription). The structure is NOT capitation (no fixed per-member-per-month regardless of usage), NOT pure shared-savings (no percentage-of-savings split), NOT pure PMPM (the PMPM claim is the savings not the price). It's closer to a risk-shifted bundled fee with binary outcome triggers — and Virta's 2025-2026 layer of cost guarantees (0% YoY GLP-1 growth, 1:1 ROI) push it further toward a capacity-based-pricing model the payer can underwrite without modeling individual member journeys.

LLY-longevity-v1 thesis impact: Additive, not substitutive — but with a named bear-case linkage worth tracking. Two concrete updates to the LLY thesis:

The "Medicare negotiation" disqualifier gains a named operating mechanism. If CMS or large MA plans look for BATNA against Mounjaro/Zepbound pricing in 2027-2028 negotiation rounds, Virta is the most credible "lifestyle-first costs less than GLP-1" operating proof point. Virta scaling from 12M to 30M+ covered lives by 2028 would meaningfully strengthen payer negotiating leverage. Action: add a Virta covered-lives + ASO/Medicare partnership tracker to the LLY-thesis quarterly review. Trigger: if Virta crosses 25M covered lives by Q2 2027, that's a meaningful update to the LLY pricing-pressure bear-case calibration.
The Virta + LLY co-existence at the employer level is the realistic 2027-2030 baseline. Carrum Health partnership (2026) and Capital Rx Rx Reverse (2025-2026) both bundle Virta with GLP-1 access in the same employer benefit. This is the "triage stack" — Virta as first-line for lifestyle-responsive T2D + obesity, GLP-1 as second-line / non-responder / contraindicated-for-lifestyle. The LLY thesis revenue model assumes 20% of US adults eligible for GLP-1; the realistic 2030 number is closer to 12-15% if the triage stack is the dominant employer benefit shape, because Virta reversal captures the 5-8% who lifestyle-respond first. This is a margin-of-error refinement on the LLY thesis, not a disqualifier — the franchise still wins because the non-responder GLP-1 population is larger than the lifestyle-responsive Virta population at population scale.

Reconciling with the 13% body-weight-loss claim: Virta's headline "13% sustained weight loss" is mean across engaged members at 1-2 years on the diabetes program. This is materially less than GLP-1 outcomes (semaglutide ~15-17%, tirzepatide ~22-23%, retatrutide ~28-30% in published phase 3) but with three structural differences: (a) no ongoing drug cost (de-prescription is the value), (b) no GLP-1 side-effect / discontinuation drag (Virta retention is the variable), (c) durable beyond treatment if the dietary protocol sticks (vs GLP-1 weight regain on discontinuation, ~67% at 1-year per STEP-4 extension data). The 13% number understates Virta's value to a payer underwriter because the comparator isn't peak-GLP-1 weight loss, it's the present-value of de-prescription + comorbidity-avoidance over 5-10 years. This is exactly why Virta can credibly guarantee 1:1 ROI with $900-$2,808 fees against $10K+ per-patient claims-avoidance.

RDCO direct relevance beyond the investing thesis: Virta's contract structure is the operating reference point for the [[2026-05-10-data-sovereignty-outcome-procurement-bet-architecture]] VBC leg. Specifically: their flat-fee-with-outcome-triggers + cost-guarantee-overlay is a cleaner pattern for an RDCO Phase-1 MVP than pure shared-savings (which requires actuarial modeling sophistication RDCO doesn't have yet) or capitation (which requires risk-bearing reserves RDCO can't fund). The Virta shape is implementable by a 10-person operator in a focused condition vertical, which is exactly the Phase-1 scope. Action: thread the Virta contract structure explicitly into the next bet-architecture revision as the operating reference.

Open follow-ups

Virta covered-lives + ASO/Medicare partnership tracker for the LLY-longevity-v1 quarterly review — what's the cleanest data source? Sacra updates appear lagged. Q3/Q4 2026 Capital Rx + Carrum disclosures + Virta press cadence is the most timely surface.
What's Virta's actual reversal rate at 2-year, 5-year cohort follow-up? Published peer-reviewed data (Hallberg et al. 2018-2021 sequence) showed strong 2-year persistence but the 5-year sustainability data is the load-bearing question for the "durability vs GLP-1" frame. If 5-year reversal sustains at >50%, the payer present-value calculation is much stronger than the marketing claims; if it drops to <30%, the substitution case weakens materially.
Does Virta have any direct LLY relationship? Capital Rx Rx Reverse positions Virta as a GLP-1 alternative — but the formulary-management context could go either way (genuine alternative, or "we tried lifestyle, now you're approved for GLP-1" front-loading). A 30-min check on Capital Rx + Virta + Lilly relationships would clarify whether Virta is structurally adversarial to Lilly or a complementary triage partner.
CMS Health Tech Ecosystem Initiative cohort full participant list — Virta is named, but the full Diabetes & Obesity Prevention and Management pillar participant list would surface whether any LLY-adjacent or LLY-funded operator is also in cohort. If yes, that's a "Lilly is co-opting the lifestyle layer" signal worth threading into the thesis.
Carrum Health 2026 covered-lives ramp: Carrum is the partnership broker that bundles Virta + others into employer benefits. Carrum's own scale trajectory is the leading indicator for "triage stack" adoption. Sacra / Pitchbook + Carrum press cadence.
Sami Inkinen public statements 2026 on GLP-1 positioning — any walk-back from the "lifestyle first" framing toward more aggressive triage / complementary positioning? The 2026-05-22 Ferriss episode framing was the most recent ground-truth; any 2026 Q2-Q3 conference or earnings-equivalent commentary update should be tracked.

Sources

Vault:

[[2026-05-22-tim-ferriss-sami-inkinen-virta-t2d-rowing]] — Inkinen primary statement on protocol + LLY framing
[[2026-05-21-lilly-glp1-longevity-thesis]] — parent thesis; bear-case Medicare-negotiation disqualifier
[[2026-05-11-marchione-primary-care]] — VBC unit economics; primary-care comp
[[2026-05-10-data-sovereignty-outcome-procurement-bet-architecture]] — VBC-leg comp for RDCO bet

Web (accessed 2026-05-24):